Tyris Therapeutics has developed a proprietary platform that enhances DNA-based therapies through the innovative use of their unique oDNA™ technology combined with non-viral delivery systems. This groundbreaking approach allows for the creation of re-dosable gene therapies that can be tailored to achieve specific therapeutic outcomes. The oDNA™ format is a synthetic linear closed DNA that includes only essential components such as the transgene, promoter, and other necessary sequences, enabling precise optimization for improved modulation of transgene properties. This technology offers significant advantages over traditional plasmid formats, including the ability to avoid immune responses and accommodate unlimited cargo loading capacity.

In addition to the oDNA™ technology, Tyris Therapeutics employs advanced non-viral vector technology that facilitates targeted biodistribution and cell delivery. This enables the development of next-generation gene therapies that can address a wide range of diseases, including those that currently lack effective treatments. Key features of their platform include the ability to provide lifelong disease control through redosing, personalized treatment responses via drug titration, and the capability to target specific organs and cell types without limitations on transgene size. Furthermore, their proprietary manufacturing process is designed to be simplified, efficient, and scalable, ensuring the production of high-quality gene therapies.

Spain

A groundbreaking platform that extends the reach of genetic treatments by combining unprecedented DNA optimisation with non-viral delivery.
Tyris Therapeutics has been founded to design the future of DNA-based treatments for patients suffering from life threatening diseases.

Tyris Therapeutics

Company Details